The Inhalation Capsules Market is Predict to reach USD 1.4 Billion by 2031, at a CAGR of 5.9%

Inhalation Capsules Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Inhalation Capsules Market size is expected to reach $1.4 billion by 2031, rising at a market growth of 5.9% CAGR during the forecast period.

Emerging technological advancements, the rising prevalence of respiratory conditions, the expanding demand for practical drug delivery methods, and the increasing adoption of inhalation therapies have all contributed to the substantial growth of the inhalation capsules market in recent years. Moreover, the convenience and portability offered by inhalation capsules are driving their adoption among patients and healthcare professionals. DPIs are compact, easy to use, and do not require fuel or coordination of breath, making them suitable for use across diverse patient populations, including children and the elderly. This ease of use enhances patient compliance and reduces the likelihood of medication errors, thereby improving treatment outcomes.

The Gelatin Capsules segment is leading the Global Inhalation Capsules Market by Type in 2023 thereby, achieving a market value of $823.7 Million by 2031. The gelatin capsules are specifically engineered to withstand the rigors of handling and inhalation while ensuring efficient delivery of dry powder medications into the lungs. Gelatin capsules are easy to handle and load into inhalation devices, making them convenient for patients. Moreover, some patients prefer gelatin capsules over other inhalation devices due to taste, ease of use, and perceived efficacy. This, in turn, is driving the growth of the segment.

The COPD Management segment is anticipated to have a CAGR of 6.1% during (2024 - 2031). In regions with substantial levels of air pollution and smoking, where the global prevalence of COPD is increasing, there is a greater demand for effective COPD management options, such as inhalation medications. As a result of their efficacy in reducing inflammation and facilitating bronchodilation, inhalation medications are exceptionally useful in the management of COPD symptoms. This results in enhanced lung function and an improved quality of life for affected individuals.

Full Report: https://www.kbvresearch.com/inhalation-capsules-market/

The North America region dominated the Global Inhalation Capsules Market by Region in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $464.4 Million by 2031. The Europe region is experiencing a CAGR of 5.5% during (2024 - 2031). Additionally, The Asia Pacific region would exhibit a CAGR of 6.7% during (2024 - 2031).

List of Key Companies Profiled

• Cipla Limited
• Novartis AG
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Lonza Group Ltd. (Capsugel)
• Chiesi Farmaceutici S.p.A
• Vectura Group Plc (Philip Morris International, Inc.)
• Elpen S.A.
• Healthcaps India Ltd.
• Qualicaps Co., LTD. (Roquette Freres SA)

Inhalation Capsules Market Report Segmentation

By Type

• Gelatin Capsules
• Hypromellose Capsules

By Application

• Asthma Treatment
• COPD Management
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Related Reports:

North America Inhalation Capsules Market Size, Trend 2031

• April-2024
• 100 Pages

LAMEA Inhalation Capsules Market Size, Growth Report 2031

• April-2024
• 107 Pages

Europe Inhalation Capsules Market Size | Analysis to 2031

• April-2024
• 107 Pages

Asia Pacific Inhalation Capsules Market Size | Share 2031

• April-2024
• 108 Pages